Tocilucimab: Summary of the TociDys Study - Dr. Roland Chapurlat

Tocilucimab: Summary of the TociDys Study - Dr. Roland Chapurlat at the 2023 FD/MAS Community Confernece and ICFDMAS meeting
Dr. Roland Chapurlat presented data from a study funded by the French Ministry of Health and a pharmaceutical company on the use of tocilizumab (TOI) to target interleukin-6 in fibrous dysplasia. The study involved a randomized crossover trial with 16 patients who had failed to respond to bisphosphonates. The primary endpoint was the change in serum CTX after 6 months of treatment versus baseline. The study did not show a significant change in bone turnover markers or bone pain. However, three patients experienced a substantial decrease in bone pain after retreatment with TOI. Further trials with a focus on bone pain as a primary outcome are suggested.
The FD/MAS Alliance Community Conference combined patient-centered science and real-world strategies for patients and families living with fibrous dysplasia, McCune-Albright syndrome (FD/MAS).
The FD/MAS Alliance (formerly Fibrous Dysplasia Foundation) is a community-driven 501c3 nonprofit that fosters the development of evidence-based treatments for Fibrous Dysplasia and McCune-Albright syndrome (FD/MAS). We advance research, provide education and channel the voices of individuals and caregivers with FD/MAS.